Metabolic aberrations and risk for prostate cancer

According to a newly published study of data from > 285,000 European males (the Metabolic Syndrome and Cancer Project), men with metabolic aberrations are at slightly less risk for a diagnosis of prostate cancer compared with men who have normal levels of metabolic factors … but their risk for prostate cancer-specific mortality is similar. … READ MORE …

Mortality, body mass index, and Gleason score: the relationship

New data appear to suggest that you really don’t want to be diagnosed with high-risk prostate cancer if you are significantly over-weight or obese. … READ MORE …

Short-term outcomes after prostate cancer diagnosis and treatment in France

An article available in full on the Medscape web site provides an overview of short-term outcomes of > 43,000 men diagnosed with prostate cancer in France in 2009 and followed for 2 years based on data in the French national health insurance information system (SNIIRAM). You do need to register with Medscape to be able to read the article (but registration is free). … READ MORE …

Over-use of PSA testing in men > 65 with short life expectancies?

Why is it that we seem to be so focused on testing for risk of prostate cancer in older men with life expectancies of < 10 years, i.e., men who are almost certainly at very low risk for clinically significant disease? … READ MORE …

Prostate cancer mortality rates in the UK drop by 21 percent

According to a report in the Daily Telegraph, Cancer Research UK is claiming that deaths from prostate cancer in the UK have drop by 20.8 percent during the 19-year period from 1991-93 to 2010-12. … READ MORE …

Early identification of androgen receptor gene amplification and prostate cancer risk

Historically, it has generally been assumed that androgen receptor gene amplification was a result of androgen deprivation therapy (ADT) and occurred in some 20 to 30 percent of men with castration-resistant prostate cancer (CRPC). However, … READ MORE …

ERSPC mortality data at 13 years of follow-up published

The Lancet has just published previously reported data from the European Randomized Study of Screening for Prostate Cancer (the ERSPC trial) at 13 years of follow-up. These data were first reported earlier this year at the annual meeting of the EAU, and we commented then on the significance of these data. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,142 other followers